Abstract-Nanoparticles promise to advance strategies to treat vascular disease. Since being harnessed by the cancer field to deliver safer and more effective chemotherapeutics, nanoparticles have been translated into applications for cardiovascular disease. Systemic exposure and drug-drug interactions remain a concern for nearly all cardiovascular therapies, including statins, antithrombotic, and thrombolytic agents. Moreover, off-target effects and poor bioavailability have limited the development of completely new approaches to treat vascular disease. Through the rational design of nanoparticles, nanobased delivery systems enable more efficient delivery of a drug to its therapeutic target or even directly to the diseased site, overcoming biological barriers and enhancing a drug's therapeutic index. In addition, advances in molecular imaging have led to the development of theranostic nanoparticles that may simultaneously act as carriers of both therapeutic and imaging payloads. The following is a summary of nanoparticle therapy for atherosclerosis, thrombosis, and restenosis and an overview of recent major advances in the targeted treatment of vascular disease. Visual Overview-An online visual overview is available for this article. 
C ardiovascular disease is the number one cause of death globally. 1 The low delivery efficiency, poor target specificity, or off-target activity of our therapies has contributed to the challenges we face in cardiovascular medicine. 2 Nanoparticles, on the scale of <0.1 microns in at least 1 dimension, have emerged as a powerful tool to increase the targeting selectivity of a drug and limit its distribution throughout the body. Their tunable shape, size, and surface chemistry enables nanoparticles to be programed for site-specific delivery. 3 A central goal of nanotherapy is to enhance the efficacy of a therapy and minimize side effects caused by freely delivered drug. 4 Nanoparticles achieve this through rational design, frequently incorporating knowledge of normal versus diseased biology to optimize residence time in the diseased tissue.
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Oncology was the first field to leverage the properties of nanoparticles for drug delivery with Doxil-a liposomeencapsulated doxorubicin formulation approved by the Food and Drug Administration in 1995 for the treatment of Kaposi sarcoma. 5 Now widely used for the treatment of multiple myeloma and other malignancies, the nanoformulation enables preferential uptake by cancer cells and limits exposure to the heart, reducing the risk of doxorubicin-induced cardiotoxicity and heart failure. 6 Currently, >50 nanoparticle-based therapies are used for a variety of indications, including infections, chronic kidney disease, and even psychiatric conditions. 7 Nanotechnology has also expanded into the realm of cardiovascular disease. Currently marketed nanoformulations of fenofibrate are used in patients with hypertriglyceridemia to help overcome challenges with drug solubility and absorption. A number of delivery systems are under development to therapeutically target pathways of vascular disease ( Figure 1 ). Additionally, multifunctional theranostic nanoparticles hold promise for combined delivery of therapeutic and imaging agents. These theranostic nanoparticles can serve to blend treatment with information from 1 or even multiple imaging modalities to more comprehensively assess disease. Prior work has highlighted the status of nanomaterials in cardiovascular imaging, including their potential to separately identify vulnerable plaques at risk for rupture. 8 This review discusses advances in the application of nanoparticles for the treatment of vascular disease, their potential translation to the clinic, and challenges in their development. Greater emphasis is placed on nanoparticle-directed therapy for atherosclerosis and its associated complications, including thrombosis and restenosis, given their role in ischemic heart disease ( Table 1) .
Resolving Inflammation and Defective Efferocytosis
Atherosclerosis is an inflammatory disease characterized by the accumulation of lipids, diseased cells, and necrotic debris. Proinflammatory leukocytes and cytokines act at different stages during the formation of the atherosclerotic plaque. 49 Heightened inflammation is driven, in part, by the failure to clear apoptotic tissue from the diseased vessel wall because of a defect in efferocytosis (programed cell removal), such that apoptotic cells accumulate, become secondarily necrotic, and release their proinflammatory intracellular contents. 50, 51 Importantly, this nonresolving inflammation drives clinically dangerous lesions that are at increased risk of rupture and thrombosis. The recent CANTOS trial (Canakinumab Anti-Inflammatory Therapy Outcomes Study) demonstrated the benefit of suppressing inflammation on cardiovascular disease in high-risk patients. 52, 53 However, targeting inflammation systemically also has significant potential to inhibit innate immunity and compromise host defense against infections. 54 Indeed, deaths because of infection or sepsis were more common among CANTOS trial patients who received the systemic anti-inflammatory treatment. Because of their ability to achieve local delivery, atherosclerosis-targeted nanoparticles may be able to address these risks.
Type IV collagen is a major subendothelial basement membrane protein that is exposed upon vascular injury and inflammation. 55 When combining a type IV collagen-targeting peptide and proresolving peptide derived from annexin A1, there was a 70% increase in selectivity of the nanoparticles for atherosclerotic lesions, relative to the spleen and liver. 15 The targeted, inflammation-resolving nanoparticles enhanced resolution to a much greater extent than the free-resolving peptide, where nanoparticle treatment effectively suppressed plaque oxidative stress, necrosis, and fibrous cap thinning. In another study using a similar type IV collagen-targeting system, nanoparticles that incorporate the anti-inflammatory cytokine IL (interleukin)-10 were engineered.
9 IL-10 nanotherapy had similar protective effects on advanced atherosclerosis in Ldlr −/− mice, in addition to enhancing macrophage-mediated clearance of apoptotic debris. Resolving local inflammation thus also appeared to have a proefferocytic effect. Short-term toxicity studies revealed no alterations in blood cytokine levels, suggesting the IL-10 nanotherapy was specific to sites of inflammation and may not compromise host defense. In a study using a nanoparticle designed to attenuate inflammation because of the production of reactive oxygen species, delivery of a free-radical scavenging payload led to a decrease in cell apoptosis within the plaques of apoE −/− mice. Following internalization by macrophages and vascular smooth muscle cells (VSMCs), the reactive oxygen species-scavenging nanoparticles decreased cellular oxidized LDL (low-density lipoprotein) uptake and subsequent transformation to foam cells. Nanoparticles were thus able to overcome the rapid elimination and short retention time of the free therapeutic agent in atherosclerotic plaques. Additionally, their benefit on plaque progression and stability was importantly observed without side effects, indicated by normal clinical chemistry, hematology, and viability of mice following treatment. 16 Inflammation-targeting nanoparticles have also been formulated as theranostic nanoparticles. In a rabbit model of atherosclerosis, magnetic resonance imaging (MRI)-detectable liposomes were developed for delivery of prednisolone to the inflamed vessel wall. 17 Liposomal encapsulation improved the pharmacokinetics of prednisolone and prolonged its circulating half-life, without systemic toxicity. After a single dose, rapid and sustained decreases in plaque inflammation were observed by MRI and correlated with 18F-FDG positron emission tomography/computed tomography-a validated method of tracking inflammation in atherosclerosis imaging. 56 Decreases in plaque inflammation were attributable to a decrease in monocyte chemoattracts and lesional macrophage density-effects that were observed to a much lesser degree in rabbits treated with the free corticosteroid. Investigators then executed a pharmaceutical development program in which they optimized a scaled-up synthesis method and formed a purified and storage-stable good manufacturing practice-grade product. 57 Following pharmacokinetic and toxicological evaluation in healthy rats and rabbits, the prednisolone-containing liposomes failed to induce measurable effects on arterial wall inflammation in phase I/II trials. 58 Optimizing the dose and treatment schedule in larger animal models may have led to a more thorough understanding of the therapeutic margin and dose required to achieve efficient target engagement. Despite the lack of treatment benefit, multimodal imaging demonstrated that the nanoparticles accumulated in plaque macrophages without adverse effects, thus serving as a guide for imaging-based efficacy measures and demonstrating the feasibility of targeting nanoparticles to human atherosclerotic areas.
In a study specifically aiming to interfere with leukocyte recruitment into the atherosclerotic plaque, Sager et al 18 combined small interfering RNA (siRNA) targeting multiple cell adhesion molecules into a polymer-based nanoparticle. Made up of a variety of synthetic or natural polymers, polymeric nanoparticles are more resistant to degradation and offer a more tunable architecture than liposomes. 59 In apoE −/− mice that underwent coronary ligation, treatment with nanoparticles encapsulating 5 siRNAs targeting leukocyte adhesion molecules significantly reduced vascular inflammation after myocardial infarction. 18 The resultant decrease in leukocyte accumulation led to a decrease in tissue injury and necrotic core formation following ischemic insult. Altogether, these studies exemplify the exciting possibility that plaque inflammation and apoptotic cell accumulation can be directly addressed using targeted nanoparticles.
Preventing Plaque Neovascularization
Advanced atherosclerotic plaques frequently display extensive adventitial and neointimal neovascularization. In humans, increased plaque vascularity has been observed in lesions from patients with acute coronary syndrome and symptomatic carotid stenosis, relative to individuals with stable or asymptomatic disease. 60, 61 These data suggest that plaque neovascularization may have an important role in atherogenesis and intraplaque hemorrhage. 62 Angiogenesis is coordinated by a number of cytokines, including VEGF (vascular endothelial growth factor) and platelet-derived growth factor. 63 Anti-VEGF therapies and other antiangiogenic agents have successfully been used to promote regression of tumor vessels and prolong survival in patients with cancer in some studies 64, 65 but come with an increased risk of arterial thromboembolic events that is further compounded in patients with a history of cardiovascular disease. 66 Based on prior work demonstrating that high-dose antiangiogenic therapy reduces plaque development in apoE −/− mice, investigators developed a targeted theranostic nanoparticle in efforts to avoid the drug's neurocognitive effects and combine an imaging agent for serial monitoring of neovessel formation. 19 Using a ligand for the α v β 3 -integrins that are upregulated during angiogenesis, hyperlipidemic rabbits treated with the MRI-detectable nanoparticles exhibited a reduction in α v β 3 -related signal enhancement in the aorta. T 1 -weighted MRI signal in the aorta correlated with the degree of neovessel formation in the atherosclerotic aorta. Interestingly, this benefit occurred at a dosage of 50 000× less when the antiangiogenic agent was encapsulated as a nanoformulation than when the therapy was delivered alone. In a follow-up study, combining their α v β 3 -targeted antiangiogenic treatment with atorvastatin achieved a greater and more sustained decrease in MRI signal and plaque neovessel count of hyperlipidemic rabbits. 20 This finding is in line with work suggesting that statins inhibit endothelial proliferation and VEGF production, potentially explaining the synergistic effect on plaque neovessel formation. 67 By leveraging plaque biology, these ), prevent plaque neovascularization (eg, α v β 3 -targeted antiangiogenic NPs 10 ), and deliver antiproliferative or thrombolytic drugs to address restenosis and atherothrombotic events (eg, endothelial-targeted NPs encapsulating paclitaxel 11 and VWF [von Willebrand factor]-targeted NPs encapsulating tPA [tissue-type plasminogen activator] 12 ). Nanoparticles have also enabled cell-specific modulation of molecules that drive atherosclerosis, such as CD40 (cluster of differentiation 40)-induced TRAF6 (tumor necrosis factor receptor-associated factor 6) signaling in macrophages 13 and regulation of PCSK9 (proprotein convertase subtilisin/kexin type 9) in hepatocytes.
14 HDL indicates high-density lipoprotein. studies highlight the potential of nanoparticles to feature an imaging/therapeutic payload and prevent disease in ways that were previously inaccessible because of off-target effects.
Targeting Macrophages
Macrophages have a key role in atherosclerosis, from lesion initiation, foam cell formation, and by contributing to the pool of apoptotic cells that affect plaque size and vulnerability. 68, 69 Importantly, in advanced lesions, defective efferocytic activity by lesional macrophages is what causes the build-up of toxic intracellular material and subsequent plaque necrosis. Several nanotherapies have been described that target plaque monocyte recruitment and infiltration, 21, 22, 28 macrophage proliferation, 23, 24 cholesterol metabolism, 25, 26 and polarization to a less-inflammatory M2 phenotype. 27 In a study by Lewis et al, 26 sugar-based nanoparticles were designed to block oxidized LDL uptake from macrophage SRs (scavenger receptors) by both direct inhibition and long-term downregulation of SR expression on the cell surface. Binding to macrophage SRs was shown to directly correlate with targeting of nanoparticles to established atherosclerotic plaques. They reported that treatment resulted in markedly reduced lipid burden and overall plaque occlusion in the aorta of apoE −/− mice. In another recent study, a targeted nanoimmunotherapy was developed to block CD40 (cluster of differentiation 40)-induced TRAF6 (tumor necrosis receptor-associated factor 6) in monocytes and macrophages, thereby preventing monocyte recruitment into the arterial wall. 13, 28 While systemic inhibition of the CD40-TRAF6 axis results in serious complications, such as thromboembolic events and immune suppression, investigators selectively targeted TRAF6 in monocytes by incorporating TRAF6 inhibitors into recombinant HDL (high-density lipoprotein) nanoparticles (TRAF6i-HDL). As an extension of the group's experience with HDL particles in atherosclerosis nanotherapy 23 and in vivo imaging, 70 TRAF6i-HDL was shown to both hamper the initiation of disease in young apoE −/− mice with no atherosclerosis and induce a more stable plaque phenotype in animals with established disease. After incorporation with fluorescent dyes or radiolabeled molecules, TRAF6i-HDL was shown to accumulate primarily in the liver and spleen of apoE −/− mice and nonhuman primates. Investigators also provided evidence of the short-term safety of the nanoimmunotherapy in mice and cynomolgus monkeys. 13 These safety experiments revealed that TRAF6i-HDL did not elicit adverse immune responses, alter major serological parameters, or cause any organ toxicity, although an 18F-FDG indicates 2-deoxy-2-(fluorine-18)fluoro-D-glucose; apoB, apolipoprotein B; apoE, apolipoprotein E; CCR2, C-C chemokine receptor type 2; CETP, cholesteryl ester transfer protein; CT, computed tomography; FMT, fluorescence molecular tomography; GP IIb/IIIa, platelet glycoprotein IIb/IIIa; HDL, high-density lipoprotein; ICAM1, intercellular adhesion molecule 1; IL-10, interleukin-10; LDL, low-density lipoprotein; MRI, magnetic resonance imaging; NADPH, nicotinamide adenine dinucleotide phosphate; NIRF, near-infrared fluorescence; NOX2, NADPH oxidase 2; NP, nanoparticle; PAA, polyacrylic acid; PCSK9, proprotein convertase subtilisin/kexin type 9; PDGF, platelet-derived growth factor; PEG, polyethylene glycol; PEI, polyethyleneimine; PET, positron emission tomography; PFC, perfluorocarbon; PLA, polylactic acid; PLGA, poly lactide-co-glycolide; ROS, reactive oxygen species; siRNA, small interfering RNA; SR, scavenger receptor; tPA, tissue-type plasminogen activator; TRAF6, tumor necrosis factor receptor-associated factor 6; TRPV1, transient receptor potential cation channel subfamily V member 1; VCAM1, vascular cell adhesion molecule 1; VSMC, vascular smooth muscle cell; and VWF, von Willebrand factor. *Nanoparticles designed as theranostic agents. acute increase in alkaline phosphatase levels and reticulocyte count was noted in mice treated for 1 week. In mice that received long-term treatment, these changes were not observed, although interestingly, cholesterol levels and white blood cell counts were both elevated in mice treated for 6 weeks. 28 Because the HDL nanoparticles primarily accumulate in the liver and spleen, further toxicological studies are needed for this promising nanoimmunotherapy. The preferential uptake of nanoparticles by inflammatory monocytes and macrophages has also served as a means for focal therapy of inflamed lesions. Iron oxide nanoparticles undergo uptake by macrophages (>75%) and to a lesser degree by neutrophils and other vascular cells. 71 When modified with a near-infrared fluorophore, irradiation of the atheroma resulted in focal ablation of the macrophage-rich plaques of mice following carotid ligation. 29 However, the authors note the phototoxicity also may affect other cell types with an affinity for the nanoparticles, including VSMCs and endothelial cells. Subjecting these cell types to photothermal therapy could potentially make the plaques more dangerous and prone to rupture. Nanoparticles that may be more cell specific are under development, including single-walled carbon nanotubes (SWNTs; Figure 2A) . 30 SWNTs undergo highly selective uptake by inflammatory Ly-6C hi monocytes. 72 Within the diseased vessels of carotid-ligated mice, SWNTs colocalized with lesional macrophages, with negligible amounts observed in VSMCs. 30 Further exploration of in vivo efficacy and therapyloading ability is needed. Given that inflammatory monocytes represent the majority of circulating cells recruited to the atherosclerotic plaque, there is compelling rationale for the use of SWNTs and other nanoparticles that afford similar cell-specific drug delivery. Moreover, SWNTs and other carbon nanomaterials exhibit a natural photoacoustic contrast and near-infrared fluorescence signal. 30, 73 These intrinsic imaging capabilities make carbon nanomaterials particularly useful for theranostic strategies to detect and treat the inflamed vulnerable plaque.
Altering Lipid Metabolism
Nanoparticle delivery systems have particularly impacted the ability to target liver cholesterol metabolism using RNA interference. A liposomal formulation of apoB (apolipoprotein B) siRNA resulted in specific silencing of apoB in hepatocytes and reductions in apoB, LDL, and total cholesterol levels in rodents and monkeys. 31, 32 The opportunity to target apoB is particularly exciting given genetic and epidemiological studies that suggest the clinical benefit of lowering LDL may depend on a corresponding reduction in apoB levels. 75 Most recently, siRNA silencing of PCSK9 (proprotein convertase subtilisin/kexin type 9) shows promise as a future strategy for reducing LDL cholesterol in a potent and convenient manner. The field of RNA interference therapy has historically been impeded by the instability of naked siRNA in the bloodstream and their inability to cross the cell membrane. RNA silencing of PCKS9 using lipid-based nanoparticles, termed lipidoids ( Figure 2B) , has recently been shown to efficiently target and suppress PCSK9 synthesis in the liver. Unlike the currently available PCSK9 antibodies (ie, evolucumab) that require biweekly injections, the novel nanoformulations of PCSK9 siRNA (inclisiran) caused rapid and durable effects after a single dose. First shown in rodents and monkeys, 14 inclisiran effectively reduced levels of PCSK9 and LDL for at least 6 months in phase 1/2 trials. [76] [77] [78] [79] Further evaluation is ongoing in phase III trials (NCT03399370). This development is a major advance in cardiovascular medicine and was driven by nanotechnology that enabled stable delivery of RNA interference therapeutics. 74 In another recent study, antibodies against the VSMCexpressed ion channel, TRPV1 (transient receptor potential vanilloid subfamily 1), were conjugated to copper sulfide nanoparticles.
33 TRPV1 induces autophagy in VSMCs, reduces lipid accumulation, and prevents foam cell formation. On irradiation of the aortic arch of apoE −/− mice, the local increase of temperature opened TRPV1 channels and allowed an influx of calcium ions to activate autophagy. Excitingly, nanoparticles provided highly precise, noninvasive treatment under image guidance because of the characteristic near-infrared absorption of copper sulfide nanoparticles that generates a strong photoacoustic signal.
Preventing Neointimal Growth
High restenosis and reintervention rates are still a significant limitation of revascularization procedures, particularly among patients with peripheral artery disease. A number of nanoparticles have been identified that enhance retention of antirestenotic agents in the local vascular bed. 80, 81 These include nanoparticles that are delivered locally via catheter, implanted in stents, and even systemically administered surrounding the time of revascularization.
Using an endovascular microinfusion catheter for local delivery, albumin-bound rapamycin nanoparticles were concentrated in the adventitial and medial layers of the arterial wall and reduced luminal stenosis in a porcine femoral artery balloon angioplasty model. 34 Rapamycin levels in the femoral artery remained >100× higher in the perivascular tissues than in the blood for 8 days. Importantly, this period was when cell proliferation rates were the highest in control animals, suggesting that the nanoparticles promote drug retention during a particularly critical period of neointima formation. In another study, Cyrus et al 10 developed α v β 3 -targeted paramagnetic nanoparticles for delivery of rapamycin to balloon injured femoral arteries of rabbits. Local infusion of vessel wall-targeted nanoparticles resulted in a decrease in neointimal formation, and their retention in the injured walls was amenable to MRI because of the high-contrast potential of paramagnetic nanomaterials. Highlighting the tunable properties of nanoparticles, NO gas and RNA interference components have also been encapsulated within nanoparticles and delivered locally to the diseased arterial wall. 35, 36 The surfaces of stents may also be loaded or targeted with nanoparticles. In a study by Chorny et al, 37 stent-targeted magnetic nanoparticles were designed. After stent placement in the carotid artery of rats, these paclitaxel-loaded nanoparticles were infused in the isolated artery and were targeted to the stent by applying a magnetic field to the body surface. Treatment effectively inhibited in-stent stenosis at drug doses below those provided by paclitaxel-eluting stents. Innovative nanoparticle-eluting stents have also been developed to prevent stenosis after stent implantation. 38, 39, 82 Importantly, these stents were found to prevent in-stent restenosis without delayed endothelial healing, which is a central reason for latestent thrombosis following percutaneous interventions.
Rather than requiring stent placement or advancement of a catheter for local delivery, targeted nanoparticles may enable systemic therapy for restenosis. Although a promising albumin-stabilized nanoformulation of paclitaxel failed to show efficacy in early clinical trials, 40, 83, 84 this work highlighted the existing space for more targeted or precision medicine approaches to restenosis nanotherapy. Using lipid-polymeric nanoparticles that were surface modified with type IV collagen-targeting peptides, Chan et al 11 reported the efficacy of paclitaxel-encapsulated nanoparticles that preferentially localized to the denuded vessel wall. Systemically administered nanoparticles led to a reduction in arterial stenosis in a rat carotid injury model. While 15 mg/kg doses of free paclitaxel induced signs of toxicity, nanoparticles enabled higher 35 mg/kg doses that were well tolerated in animals. Another group described a liposomal formulation of the bisphosphonate alendronate that reduced neointimal formation by transiently suppressing circulating monocyte levels in rabbits that had undergone iliac artery stenting. 41 Early-phase clinical trials supported the safety of liposomal alendronate for infusion at the time of percutaneous coronary intervention. Although there was no difference in restenosis rates between the treatment and placebo groups, the anti-inflammatory nanoparticle led to a significant reduction in in-stent late loss in an inflammatory patient subgroup with elevated baseline monocyte counts (NCT02645799). 85 Other systemic nanoformulations that have prevented restenosis include NO-containing nanofibers 42 and glucocorticoid-encapsulated nanoparticles that are targeted to subendothelial matrix proteins. 43 Taken together, nanoparticle-based delivery may be a useful adjunct to revascularization procedures, particularly for patient-personalized treatment and for those with diffuse disease and other challenging lesion patterns.
Targeting Thrombosis
Platelet activation, the coagulation cascade, and fresh thrombus include unique factors that enable targeted delivery of therapeutic agents. Thrombus-targeted nanoparticles have been developed for delivery of thrombolytic agents and anticoagulants, including tPA (tissue-type plasminogen activator), 12, 44, 45 streptokinase, 46, 86 urokinase, 47, 87 and direct thrombin inhibitors. 48 By encapsulating a von Willebrand factor-binding protein within nanoparticles, investigators effectively targeted tPA to thrombi induced in swine coronary arteries. 12 Intravenous delivery of nanoparticles resulted in reperfusion and vessel recanalization in 90% of animals. Interestingly, nanoparticles were designed for controlled release of tPA using transthoracic ultrasound, where application of ultrasound led to greater tPA offloading and thrombolytic activity at the affected artery. In another study, antithrombin theranostic nanoparticles directly attenuated plaque coagulant activity within the injured arteries of apoE −/− mice. 48 Detectable by magnetic resonance spectroscopy, systemically administered nanoparticles were retained within the plaques and exerted rapid inactivation of any locally produced thrombin. These effects were observed without altering activated partial thromboplastin time or other systemic effects on coagulation. Moreover, focal inhibition of plaque thrombin reduced the expression of plaque inflammatory molecules and enhanced restoration of the disrupted vascular endothelium, suggesting the antithrombin nanoparticles promoted plaque stability. Taken together, these studies illustrate the broad potential that nanoparticles have for reperfusion therapy and anticoagulation with decreased bleeding consequences.
Conclusions and Future Directions
Target-driven nanoparticles have opened the door to improved and even novel treatment options for patients with vascular disease. Those that have advanced into early clinical trials provide important lessons, namely the need for (1) a well-defined patient population most likely to benefit from therapy and (2) a thorough understanding of a formulation's therapeutic margin. In addition to implementing clinically relevant animal models, these considerations will greatly draw from the use of biomarker and molecular imaging-based strategies to enable patient selection and assessment of drug accumulation and response.
Nonetheless, there are important limitations and challenges in cardiovascular nanomedicine that should be noted (Table 2) . First, nanoparticles are inherently heterogeneous in composition and can present challenges in synthesis of large volumes that adhere to pharmaceutical good manufacturing practice guidelines (eg, sterility, stability, and purity). It will be important to develop methods to scale-up production with high reliability and reproducibility, reasonable cost, and time efficiency for successful translation from bench-to-bedside. Moreover, stability in circulation and during storage is a common pitfall of nanotechnology. Although conventional methods for quality control exist, each nanoformulation is a specialized unit and requires unique measurements of physicochemical properties and drug release rates. In particular, there is a need to develop a drug release profile under both physiological and storage conditions, such that the drug is not released too slowly, prematurely in circulation or even during storage. In addition, although some nanoformulations use disease-targeting ligands, several nanoparticles have been described to have an intrinsic affinity for certain cell types (eg, intraplaque macrophages). The distinct mechanisms by which such nanoparticles are taken up by cells are poorly understood and is an intriguing area for future study. Lastly, there is a major gap in the evaluation of the long-term safety of nanoformulations in vivo. Many currently available nanoformulations were developed to reduce the side effects of a loaded drug, but some nanoparticles undergoing preclinical development have retroactively been discovered to be cytotoxic or immunogenic. 88 In an ideal situation, these studies will be pursued in parallel as a means of informing decisions earlier in the development process. Coating nanoparticles with polyethylene glycol, or PEGylation, is a commonly used approach for reducing their systemic toxicity and interaction with plasma proteins and circulating cells. 89 Further optimization of methods to reduce unwanted nano-bio interactions may be necessary.
Although there has been substantial progress, the global epidemic of vascular disease and resultant deaths are predicted to increase during the next decades, affecting developed and developing nations alike. 90 Lipid-lowering therapies are the dominant treatment for atherosclerosis, but there is much room for improvement with complementary therapies. Our understanding of plaque biology has evolved to include inflammatory mechanisms and impaired efferocytosis as causal drivers of lesion progression and instability. However, anti-inflammatory therapies are known to cause immunosuppression. Additionally, reactivating efferocytosis has the drawback of inducing the off-target clearance of healthy tissues under some conditions. For example, in addition to efficiently restoring phagocytosis and preventing atherosclerosis, proefferocytic therapy also caused a clinically relevant anemia because of clearance of red blood cells in the spleen. 91, 92 To overcome the toxicities associated with anti-inflammatory and proefferocytic approaches, it is likely that nanoparticles will serve as the innovative delivery systems that will enable targeting of these important pathways specifically within the vulnerable plaque. 
